Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Aug;170(4):590-3.
doi: 10.1111/bjh.13319. Epub 2015 Feb 25.

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

Tapan Kadia  1 , Hagop Kantarjian  1 , Guillermo Garcia-Manero  1 , Gautam Borthakur  1 , Xuemei Wang  2 , Keyur Patel  3 , Elias Jabbour  1 , Mark Brandt  1 , Naval Daver  1 , Naveen Pemmaraju  1 , Sherry Pierce  1 , Jorge Cortes  1 , Farhad Ravandi  4
Affiliations
Clinical Trial

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

Tapan Kadia et al. Br J Haematol. 2015 Aug.
No abstract available

Keywords: acute myeloid leukaemia; cytogenetics of leukaemia; prognostic factors.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure: The authors have no relevant conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Distribution of patients < 60 years (N=487) by the European Leukaemia Net (ELN) (A) and UK Medical Research Council (MRC) (C) classification systems. Distribution of the patients ≥ 60 years (N=539) by the ELN (B) and MRC (D) classification systems. Bottom panel: Overall survival of patients < 60 years (N=487) classified by the ELN (E) and MRC (F) classifications systems. Overall survival of patients ≥ 60 years (N=539) classified by the ELN (G) and MRC (H) classification systems. FAV, favourable; INT, intermediate; ADV, adverse
Figure 1
Figure 1
Distribution of patients < 60 years (N=487) by the European Leukaemia Net (ELN) (A) and UK Medical Research Council (MRC) (C) classification systems. Distribution of the patients ≥ 60 years (N=539) by the ELN (B) and MRC (D) classification systems. Bottom panel: Overall survival of patients < 60 years (N=487) classified by the ELN (E) and MRC (F) classifications systems. Overall survival of patients ≥ 60 years (N=539) classified by the ELN (G) and MRC (H) classification systems. FAV, favourable; INT, intermediate; ADV, adverse
See this image and copyright information in PMC

References

    1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474. - PubMed
    1. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–365. - PubMed
    1. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ, Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, KalickiVeizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G, Alonso S, Ayala B, Baboud J, Backus M, Barletta SP, Berton DL, Chu AL, Girshik S, Jensen MA, Kahn A, Kothiyal P, Nicholls MC, Pihl TD, Pot DA, Raman R, Sanbhadti RN, Snyder EE, Srinivasan D, Walton J, Wan Y, Wang Z, Issa JP, Le Beau M, Carroll M, Kantarjian H, Kornblau S, Bootwalla MS, Lai PH, Shen H, Van Den Berg DJ, Weisenberger DJ, Link DC, Walter MJ, Ozenberger BA, Mardis ER, Westervelt P, Graubert TA, DiPersio JF, Wilson RK for the Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–2074. - PMC - PubMed
    1. Mrozek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP, Metzeler KH, Schwind S, Wu YZ, Kohlschmidt J, Pettenati MJ, Heerema NA, Block AW, Patil SR, Baer MR, Kolitz JE, Moore JO, Carroll AJ, Stone RM, Larson RA, Bloomfield CD. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30:4515–4523. - PMC - PubMed
    1. Rollig C, Bornhauser M, Thiede C, Taube F, Kramer M, Mohr B, Aulitzky W, Bodenstein H, Tischler HJ, Stuhlmann R, Schuler U, Stolzel F, von Bonin M, Wandt H, Schafer-Eckart K, Schaich M, Ehninger G. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29:2758–2765. - PubMed

MeSH terms